| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 12/29/2010 | WO2010149772A1 Preparation comprising insulin, nicotinamide and an amino acid |
| 12/29/2010 | WO2010149326A1 Acid-labile trigger units |
| 12/29/2010 | WO2010149215A1 Artesunate pharmaceutical compositions soluble in aqueous solutions |
| 12/29/2010 | WO2010149196A1 Taste masked dosage form of pharmaceutically acceptable salt of escitalopram |
| 12/29/2010 | WO2010148653A1 Polymer vesicles of asymmetric membrane |
| 12/29/2010 | WO2010148501A1 Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery |
| 12/29/2010 | WO2010131032A3 Novel polymers |
| 12/29/2010 | WO2010122474A3 A medicinal antifungal and steroid cream incorporating a biopolymer and a process to make it |
| 12/29/2010 | WO2010122473A3 A medicinal antifungal and steroid cream incorporating a biopolymer and a process to make it |
| 12/29/2010 | WO2010119389A3 Pretargeting kit, method and agents used therein |
| 12/29/2010 | WO2010063998A3 Antibiotic nanomaterial |
| 12/29/2010 | WO2010008582A3 Phagocytic cell delivery of rnai |
| 12/29/2010 | WO2009132048A8 Treating eosinophilic esophagitis |
| 12/29/2010 | EP2267452A1 A soluble complex comprising a retroviral surface glycoprotein |
| 12/29/2010 | EP2267026A1 Albumin fusion proteins |
| 12/29/2010 | EP2266986A1 Cytotoxins, Prodrugs, Linkers and Stabilizers useful therefor |
| 12/29/2010 | EP2266964A1 Acid-labile trigger units |
| 12/29/2010 | EP2266889A2 Injection-moulded water-soluble container |
| 12/29/2010 | EP2266626A1 Composition for external application comprising transcription factor decoy as active ingredient |
| 12/29/2010 | EP2266625A2 Prodrugs Containing Novel Bio-Cleavable Linkers |
| 12/29/2010 | EP2266624A2 Duramycin peptide binding to anionic phospholipids and aminophospholipids conjugates and their use in treating viral infections |
| 12/29/2010 | EP2266623A2 Prodrugs containing novel bio-cleavable linkers |
| 12/29/2010 | EP2266622A2 Prodrugs containing novel bio-cleavable linkers |
| 12/29/2010 | EP2266607A2 Immunoconjugates for treating cancer |
| 12/29/2010 | EP2266600A2 Therapeutic composition with a botulinum neurotoxin |
| 12/29/2010 | EP2266599A2 Therapeutic composition with a botulinum neurotoxin |
| 12/29/2010 | EP2266596A1 Pharmaceutical composition and a method for the production thereof |
| 12/29/2010 | EP2266590A2 Active agent delivery sytems and methods for protecting and administering active agents |
| 12/29/2010 | EP2266582A1 Pharmaceutical composition for preventing dysbiosis associated with enteral administration of antibiotics |
| 12/29/2010 | EP2266573A1 Fulvestrant formulation |
| 12/29/2010 | EP2266565A1 Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein |
| 12/29/2010 | EP2266556A1 Water-based adhesive skin patch comprising ketoprofen lysine salt |
| 12/29/2010 | EP2266553A1 Butenafine hydrochloride-containing aqueous patch |
| 12/29/2010 | EP2266552A2 Methods of inducing terminal differentiation |
| 12/29/2010 | EP2266549A2 Method of making particles for use in a pharmaceutical composition |
| 12/29/2010 | EP2266548A2 Dry powder for inhalation |
| 12/29/2010 | EP2266547A1 Composition for the transdermal delivery of fentanyl |
| 12/29/2010 | EP2266544A2 Method for encapsulating therapeutic substances in cells |
| 12/29/2010 | EP2266543A2 Non-polymeric hematopoietic cell clots for delivery of active agents |
| 12/29/2010 | EP2266542A2 Controlled release nanoparticulate compositions |
| 12/29/2010 | EP2266540A1 Pharmaceutical compositions comprising a HMG COA reductase inhibitor |
| 12/29/2010 | EP2266539A2 Methods of treatment using a gastric retained gabapentin dosage |
| 12/29/2010 | EP2266537A2 Compositions and methods for treating cancer |
| 12/29/2010 | EP2266535A2 Controlled release compositions for interferon based on block polymers |
| 12/29/2010 | EP2265623A1 Mitochondrially delivered anti-cancer compounds |
| 12/29/2010 | EP2265605A1 Dexlansoprazole process and polymorphs |
| 12/29/2010 | EP2265292A2 Method for the synthesis of hollow spheres |
| 12/29/2010 | EP2265291A2 Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration |
| 12/29/2010 | EP2265290A1 Oligomer-aryloxy-substituted propanamine conjugates |
| 12/29/2010 | EP2265289A2 Compositions and methods for tissue-specific rnai delivery in vivo |
| 12/29/2010 | EP2265283A1 Auristatin drug linker conjugates |
| 12/29/2010 | EP2265256A1 Dithiocarbamate metal chelates and methods of making and using thereof |
| 12/29/2010 | EP2265174A1 Functionalized magnetic nanoparticles and methods of use thereof |
| 12/29/2010 | EP2142174B1 Stable aqueous g-csf formulations |
| 12/29/2010 | EP2131822B1 Divalent metal-ion loaded nano-transport system having a dendritic architecture useful for therapy |
| 12/29/2010 | EP1771199B1 Long-acting colloidal insulin formulation and preparation thereof |
| 12/29/2010 | EP1660134B1 Conjugates of hydroxyalkyl starch and g-csf |
| 12/29/2010 | EP1621202B1 Freeze-dried preparation containing methylcobalamin and process for producing the same |
| 12/29/2010 | EP1545429B1 Compositions containing citric acid for the treatment of nail fungal infections |
| 12/29/2010 | EP1494705B1 A composition and method for killing of tumours |
| 12/29/2010 | EP1441727B1 Depot formulations of iloperidone and a star polymer |
| 12/29/2010 | EP1387673B1 Abuse-resistant controlled-release opioid dosage form |
| 12/29/2010 | EP1286657B1 Nasal ointment based on white petroleum jelly |
| 12/29/2010 | EP1197209B1 Percutaneously absorbable preparations |
| 12/29/2010 | EP1183022B1 Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response |
| 12/29/2010 | EP1077678B1 Mucoadhesive compositions for administration of biologically active agents to animal tissue |
| 12/29/2010 | CN1969032B Method of inhibiting formation of volatile aldehydes and/or decomposition of fatty acids and use thereof |
| 12/29/2010 | CN1956707B Gastroresistant pharmaceutical dosage form comprising N-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-D-glutamic acid (LK-423) |
| 12/29/2010 | CN1863558B Polyarginine-modified liposome capable of transferring into nucleus |
| 12/29/2010 | CN1857734B Phytoagglutinin modified lactic acid-hydroxacetic acid copolymer and its preparing method |
| 12/29/2010 | CN101932329A Adhesive patch |
| 12/29/2010 | CN101932317A Stable pharmaceutical composition |
| 12/29/2010 | CN101932311A Microparticles and pharmaceutical compositions thereof |
| 12/29/2010 | CN101932305A Transcutaneous pharmaceutical compositions containing a steroid hormone |
| 12/29/2010 | CN101928458A Preparation method of multifunctional nanometer composite particle constructed by modified polymine |
| 12/29/2010 | CN101928435A Macromolecular sustained-release multifunctional reinforced film and preparation method thereof |
| 12/29/2010 | CN101928355A Aminated alginic acid and preparation method thereof |
| 12/29/2010 | CN101928328A RGD peptide-epimedium flavone combination, preparation method and application thereof |
| 12/29/2010 | CN101928262A Biologically active methylene blue derivatives |
| 12/29/2010 | CN101928243A Acenaphtho heterocyclic compounds, and cyclodextrin inclusion compounds or conjugates thereof and application thereof in preparing Bcl-2 family protein inhibitors |
| 12/29/2010 | CN101927989A Method for preparing ordered nest-shaped porous hydroxylapatite material |
| 12/29/2010 | CN101927006A Preparation method of pH-responded metal organic coordination polymer based on medicament |
| 12/29/2010 | CN101927005A Method for solubilizing carbon nano tube by using super-molecular complex and controlling solubility thereof by using light |
| 12/29/2010 | CN101927004A Macromolecule slow controlled release long-acting sterilizing product and preparation method thereof |
| 12/29/2010 | CN101927003A Method for preparing pharmaceutic adjuvant film coating material |
| 12/29/2010 | CN101927002A Medicament and coating composition |
| 12/29/2010 | CN101927001A Method for loading anti-cancer drug based on multifunctional polyamidoamine dendrimer |
| 12/29/2010 | CN101927000A Medicine composite of superfine sterile sodium carbonate and cephems |
| 12/29/2010 | CN101926984A Preparation method of artificial nano red blood cells |
| 12/29/2010 | CN101926983A Artificial nano red blood cells |
| 12/29/2010 | CN101926962A Hydroxypropyl-beta-cyclodextrin inclusion liposome of zedoary turmeric oil and preparation method thereof |
| 12/29/2010 | CN101926875A Gel for treating gynecologic inflammation and preparation method thereof |
| 12/29/2010 | CN101926847A External solid ointment containing mint oil |
| 12/29/2010 | CN101926836A Pubescent holly root preparation for treating heart cerebrovascular diseases |
| 12/29/2010 | CN101926833A Hydrogel patch and preparation method thereof |
| 12/29/2010 | CN101926822A Use of silicon dioxide mesoporous material in preparation of antidote for treating heavy metal poisoning |
| 12/29/2010 | CN101926821A Drug composition for targeted release of trace elements and preparation method and application thereof |
| 12/29/2010 | CN101926816A Intravenous injection of nelarabine and preparation method thereof |
| 12/29/2010 | CN101926813A Veterinary compound anti-parasitic injection and preparation method thereof |
| 12/29/2010 | CN101926808A Glucosamine formulations |